The Instrument Segment Accounted for the Largest Share of the High-content Screening Market, While the Software Segment Is Expected to Register Highest Growth Rate

The global high-content screening (HCS) market is projected to register a CAGR of 10.3% during the forecast period. The growth of the market is attributed to factors such as cost containment in pharma R&D, growth in funding for cellular research, and technological advancements in HCS solutions during the forecast period.

The HCS market in this report is segmented on the basis of product, application, end user, and region. The cell imaging and analysis systems segment is expected to register the highest growth in the HCS instrument market. Increasing studies into cell behavior and the need to correlate multiple events and markers with cell morphology are expected to drive the growth of the market during the forecast period. Moreover, the software segment is expected to register the highest growth in HCS market during the forecast period. The growth of this market can be attributed to the technological advancements in image acquisition, data analysis, and storage capabilities and the need to obtain information on changes in cell morphology through high-quality images.

The primary & secondary screening application segment is expected to grow at the highest CAGR in the HCS market during the forecast period. The growth of this segment is attributed to the presence of a large number of potential drug candidates for target-specific delivery and significant improvements in instruments and image acquisition & data analysis software. This process facilitates the evaluation of bioavailability, lead specificity, and toxicity, which allows researchers to prioritize the leads with higher assurance and reduce late-stage attritions.

Among the end users of HCS products, the pharmaceutical and biotechnology companies segment is expected to register the highest growth during the forecast period. The major factors contributing to the growth of this segment are the use of HCS techniques in the evaluation of toxicity studies & drug mechanism of action (MOA) studies using cell-based assays and its applications in primary screening, secondary screening, compound profiling, and compound development.

Asia-Pacific region is expected to register the highest growth rate in the global HCS market during the forecast period. Factors such as increasing drug discovery research, government initiatives, growing focus of multinational companies in emerging economies, and rapidly developing R&D infrastructure are driving the growth of the HCS market in this region.